CClinicalTrials.gg
CompletedNCT01471938Updated Feb 9, 2012

Application and Adaption of Device Specific Body Composition Formulas to Various Ethnic Groups

An observational study in Bioelectrical Impedance Measurement of Healthy Adults, sponsored by Seca GmbH & Co. Kg.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-09.

Sponsored by Seca GmbH & Co. Kg. · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
130
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of the study is to apply and adapt device specific body composition formulas to various ethnic groups. Bases are prediction equations that are generated in the clinical investigation "Generation of prediction equation to analyze body composition of adults based on Bioelectrical Impedance Analysis (BIA)". The study bears the code BCA-01.

02

Conditions studied

  • Bioelectrical Impedance Measurement of Healthy Adults
03

In context

Lead sponsor

Seca GmbH & Co. Kg. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Data of 130 healthy adults are planned to be collected.

Inclusion criteria

The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.

Exclusion criteria

Exclusion Criteria:

  • acute and chronic diseases
  • regular intake of medications (except for contraceptives)
  • amputation of limbs
  • electrical implant as cardiac pacemaker
  • insulin pumps
  • artificial joints
  • metallic implants (except tooth implants)
  • claustrophobia
  • pregnancy or breastfeeding period
  • probands who cannot provide an ICF by themselves
  • probands who might be dependent from the sponsor or the inv. site
  • current alcohol abuse
  • frequent hypersensitivity reactions/allergies determ. anamnestically
  • body weight of more than 150 kg
  • extensive tattoos at arms or legs
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
130 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Caucasians

    31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.

  • Afro Americans

    31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.

  • East and Southeast Asian

    31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.

  • Hispanics

    31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.

06

What researchers measure

Primary outcomes

  1. Bioelectrical Impedance (Resistance and Reactance) of 5 and 50 kHz for one body side

    Time frame: about 1 hour

  2. Bioelectrical Impedance (Resistance and Reactance) of 50 kHz for all 4 extremities

    Time frame: about 1 hour

  3. Bone Mineral Content (BMC) based on DXA (Dual X-Ray Absorptiometry)

    BMC is used to calculate Fat Free Mass (FFM). In addition to that Body Volume, Total Body Water (TBW) and Body Weight is needed. DXA is used as reference measurement for Skeletal Muscle Mass (SMM) as well.

    Time frame: about 30 minutes

  4. Body Volume based on Air Displacement Plethysmography (ADP)

    Body Volume is used to calculate FFM in addition to DXA, TBW and Body Weight.

    Time frame: about 30 minutes

  5. TBW

    A D2O dose of 400 mg per kg body weight mixed with tap water is administered orally in the morning fasting and after a 2 hour fluid abstention. The distribution of the stable isotope in the TBW is completed after 4 hours. During this period, the subject remains fasting. Two venous blood samples of 10 ml whole blood are taken immediately before and four hours after taking D2O. The plasma samples are analyzed using Isoptopic Ratio Mass Spectrometry (IRMS).

    Time frame: within 4 hours

  6. ECW

    Orally administered NaBr is resorbed quickly and completely and almost exclusively distributes in the extracellular compartment. Blood samples of 10 ml are taken immediately before and 4 hours after oral application of 50 mg NaBr per kg body weight. The serum sample is analyzed by X-Ray Fluorescence Spectroscopy (XRF).

    Time frame: within 4 hours

Secondary outcomes

  1. Bioelectrical Impedance (Resistance and Reactance) of 1, 1.5, 2, 3, 7.5, 10, 15, 20, 30, 75, 100, 150, 200, 300, 500, 750 and 1,000 kHz

    The measurement is planned to be done for all body segments: right arm, left arm, right leg, left leg, trunk, right body side and left body side. In total resistance and reactance at 19 frequencies for 7 body segments are planned to be measured.

    Time frame: about 1 hour

  2. SMM based on Magnet Resonance Imaging (MRI)

    Time frame: about 1 hour

  3. Bioelectrical Impedance (Resistance and Reactance) in sitting, lying and standing body position

    Time frame: about 1 hour

07

Study locations

1 site
  • Body Composition of NY Obesity Research Center
    New York, New York 10025, United States
08

References and documents

Publications

  • Jensen B, Braun W, Both M, Gallagher D, Clark P, Gonzalez DL, Kluckmann K, Bosy-Westphal A. Configuration of bioelectrical impedance measurements affects results for phase angle. Med Eng Phys. 2020 Oct;84:10-15. doi: 10.1016/j.medengphy.2020.07.021. Epub 2020 Jul 30. PubMed 32977906 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01471938
Lead sponsor
Seca GmbH & Co. Kg.
Responsible party
Sponsor
First posted
Nov 16, 2011
Start date
Jul 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Feb 9, 2012

Study contacts

Dympna Gallagher, Dr.
principal investigator · St. Luke's-Roosevelt Hospital Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion